대한뉴팜

Daehan New Pharmed by global veterinary vaccine leader HIPRA for its strong cattle product sales network in Korea

- The only bovine mastitis vaccine registered with the European Medicines Agency (EMA), proven for safety and efficacy, providing dual protection against two major pathogens

- “A significant contribution to preventing chronic dairy farm diseases and advancing Korea’s veterinary and dairy industries”

Daehan New Pharm has signed an exclusive sales agreement with global veterinary vaccine company HIPRA for “Hipra Startvac,” a multivalent vaccine developed to combat bovine mastitis, and has commenced product distribution in Korea.

Through this partnership, Daehan New Pharm will begin full-scale domestic supply of “Hipra Startvac,” targeting bovine mastitis—a chronic, recurring disease in dairy farms.

“Hipra Startvac” prevents infection caused by Staphylococcus aureus and Escherichia coli, the two major pathogens responsible for bovine mastitis. As the first bovine mastitis vaccine approved by the European Medicines Agency (EMA), it has been verified for both safety and efficacy and is currently registered and sold in over 50 countries worldwide. No side effects such as abscess formation or somatic cell count increases have been reported, and clinical trials conducted on local dairy farms in Gyeonggi Province confirmed an absence of adverse reactions.

Polysaccharide biofilms formed by Staphylococcus aureus and coagulase-negative staphylococci (CNS) enable bacteria to adhere to mammary glands, inducing antibiotic resistance and high pathogenicity. “Hipra Startvac” is the only vaccine proven to inhibit and prevent this biofilm formation, thereby suppressing bacterial proliferation and neutralizing adhesion factors to effectively prevent mastitis. Unlike existing domestic competitors, “Hipra Startvac” provides cross-protection not only against S. aureus and E. coli but also against CNS and coliform bacteria—making it a truly multivalent vaccine.

The total Korean vaccine market is estimated at approximately 300 billion KRW, with foreign companies accounting for 60–70% of the domestic livestock vaccine segment. This exclusive sales agreement marks Daehan New Pharm’s first entry into the vaccine market, and with its strong presence in the cattle segment, the company anticipates sustained growth in mastitis vaccine sales.

Unlike conventional vaccines, “Hipra Startvac” has no post-injection side effects and is recommended for use even during lactation. The optimal vaccination schedule involves intramuscular injection in the neck 45 and 10 days before calving and at 50 days after calving, effectively reducing the risk of infection, economic losses, and mastitis incidence.

Kim Myung-hwi, Head of HIPRA Korea, stated, “We are delighted to grant Daehan New Pharm exclusive distribution rights for ‘Hipra Startvac,’ a vaccine with exceptional efficacy compared to competitors. Daehan New Pharm’s strong nationwide distribution network for cattle products played a key role in our decision. We hope this vaccine will help establish a preventive dairy farming culture in Korea and serve as a definitive solution to mastitis, a chronic challenge for dairy producers.”

Following this agreement, Daehan New Pharm plans to collaborate with HIPRA headquarters to provide on-site bacterial diagnostic systems and related services for dairy farms seeking to implement advanced diagnostic infrastructures.